Associate Professor of Pathology, Massachusetts General Hospital
Pathology
Dr. Anthony J. Iafrate, MD
|
|
Give Review
Anthony J. Iafrate, MD is an expert in the field of Pathology. He studied medicine at Stony Brook University School of Medicine. Dr. Anthony J. Iafrate is also published. He has 57 publications published. The lastest publication: "Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
- Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma.
- Treatment response assessment in IDH-mutant glioma patients by non-invasive 3D functional Spectroscopic Mapping of 2-Hydroxyglutarate.
- Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies.
- Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
- Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: The Lung Cancer Mutation Consortium experience.
- GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases.
- Brain tumor cells in circulation are enriched for mesenchymal gene expression.
- Identification of oncogenic mutations and gene fusions in the follicular variant of papillary thyroid carcinoma.
- Anchored multiplex PCR for targeted next-generation sequencing.
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer.
- High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome.
- High lung shunt fraction in colorectal liver tumors is associated with distant metastasis and decreased survival.
- Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
- Genome Editing: A Tool For Research and Therapy: Towards a functional understanding of variants for molecular diagnostics using genome editing.
- Clinical utility of a blood-based BRAF V600E mutation assay in melanoma.
- Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer.
- The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma.
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib.
- Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.
- Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.
- ALK Molecular Phenotype in Non-Small Cell Lung Cancer: CT Radiogenomic Characterization.
- Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
- Standardized decision support in next generation sequencing reports of somatic cancer variants.
- Genetic Mechanisms in Interval Colon Cancers.
- Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
- Deep Sequencing Identifies IDH1 R132S Mutation in Adult Medulloblastoma.
- Mutational analysis and clinical correlation of metastatic colorectal cancer.
- Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
- Inactivation of the tumor suppressor WTX in a subset of pediatric tumors.
- Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.
- Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
- ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer.
- Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.
- Acquired resistance to crizotinib from a mutation in CD74-ROS1.
- Fibrosis-Associated Single-Nucleotide Polymorphisms in TGFB1 and CAV1 Are Not Associated With the Development of Nephrogenic Systemic Fibrosis.
- BRAF V600E Mutation Identifies a Subset of Low-Grade Diffusely Infiltrating Gliomas in Adults.
- Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis.
- FGFR1 Amplification in Squamous Cell Carcinoma of The Lung.
- Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment.
- Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.
- Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses.
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
- Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults, with high proliferation index and no BCL2 rearrangement.
- Prospective, high-throughput molecular profiling of human gliomas.
- The challenges posed by cancer heterogeneity.
- Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas.
- NRAS mutations are rare in colorectal cancer.
- Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas.
- Global genomic analysis of intraductal papillary mucinous neoplasms of the pancreas reveals significant molecular differences compared to ductal adenocarcinoma.
- RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
- Genotyping Cancer-Associated Genes in Chordoma Identifies Mutations in Oncogenes and Areas of Chromosomal Loss Involving CDKN2A, PTEN, and SMARCB1.
- Pulmonary adenocarcinoma mutation profile in smokers with smoking-related interstitial fibrosis.
- Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.
- Development of a database system and image viewer to assist in the correlation of histopathologic features and digital image analysis with clinical and molecular genet...
- Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.
Schools
State University of New York Health Science Center At Stony Brook
Brigham and Women39s Hospital
Doctors Specialties
- Molecular Genetic Pathology
- Pathology
Accepted Insurances
Education
-
Brigham and Women's Hospital -
Stony Brook University School of Medicine
Hospital
-
Massachusetts General Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1164403796 |
| Last Name Of The Provider | IAFRATE |
| First Name Of The Provider | ANTHONY |
| View All |
Similar Doctors
|
|
Dr. John F. Staropoli, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sanford I. Roth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David N. Louis, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Jennifer L. Hunt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karin E. Finberg, MD |
|
|
Dr. Matija Snuderl, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Fei Dong, MD |
|
|
Dr. Janina A. Longtine, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Neal I. Lindeman, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Mel B. Feany, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. German A. Pihan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarayu Chandrashekhar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edmond J. Yunis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Roy Lee, MD
This Doctor is OpenDoctor Recommended.
|